1. INTRODUCTION
1.1. MARKET OVERVIEW
1.2. MARKET DEFINITION
1.3. SCOPE OF THE STUDY
1.4. CURRENCY
1.5. ASSUMPTIONS
1.6. BASE, AND FORECAST YEARS TIMELINE
2. RESEARCH METHODOLOGY
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. MARKET OVERVIEW AND SEGMENTATION
4.2. MARKET DRIVERS
4.3. MARKET RESTRAINTS
4.4. MARKET OPPORTUNITIES
4.5. PREVALENCE
4.5.1. BY AGE GROUP
4.5.2. BY REGION
4.6. PRODUCT PIPELINE
4.7. INNOVATIONS
5. OVARIAN CANCER TREATMENT MARKET BY DIAGNOSIS
5.1. BLOOD TESTS
5.2. IMAGING TESTS
5.3. LAPAROSCOPY
5.4. COLONOSCOPY
5.5. OTHERS
6. OVARIAN CANCER TREATMENT MARKET BY TREATMENT
6.1. SURGERY
6.2. RADIATION THERAPY
6.3. CHEMOTHERAPY
6.4. HORMONE THERAPY
6.5. CLINICAL TRIALS
7. OVARIAN CANCER TREATMENT MARKET BY GEOGRAPHY
7.1. NORTH AMERICA
7.1.1. USA
7.1.2. CANADA
7.1.3. MEXICO
7.2. SOUTH AMERICA
7.2.1. BRAZIL
7.2.2. ARGENTINA
7.2.3. OTHERS
7.3. EUROPE
7.3.1. GERMANY
7.3.2. FRANCE
7.3.3. UNITED KINGDOM
7.3.4. SPAIN
7.3.5. OTHERS
7.4. MIDDLE EAST AND AFRICA
7.4.1. SAUDI ARABIA
7.4.2. ISRAEL
7.4.3. OTHERS
7.5. ASIA PACIFIC
7.5.1. CHINA
7.5.2. JAPAN
7.5.3. SOUTH KOREA
7.5.4. INDIA
7.5.5. OTHERS
8. COMPETITIVE INTELLIGENCE
8.1. COMPETITIVE BENCHMARKING AND ANALYSIS
8.2. RECENT INVESTMENTS AND DEALS
8.3. STRATEGIES OF KEY PLAYERS
9. COMPANY PROFILES
9.1. SOTIO (MEMBER OF PPF GROUP)
9.2. PFIZER INC.
9.3. ASTRAZENECA
9.4. F. HOFFMANN-LA ROCHE LTD
9.5. TESARO, INC.
9.6. CLOVIS ONCOLOGY
9.7. ABBVIE INC.
9.8. OASMIA PHARMACEUTICAL AB
9.9. IMMUNOGEN INC.
9.10. BOEHRINGER INGELHEIM GMBH
LIST OF FIGURES
LIST OF TABLES